PIII — P3 Health Partners Inc.

Summary of P3 Health Partners Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Results: Total revenue was $384.8 million, up from $370.7 million in Q4 2024. Full-year revenue was $1.46 billion, down from $1.50 billion in 2024.
• Capitated Revenue PMPM: Increased to $1,060 in Q4 2025 from $971 in Q4 2024, reflecting a 9% improvement. Full-year PMPM was $1,026, a 5% increase from 2024.
• Adjusted EBITDA: Reported a loss of $76.1 million in Q4 and a full-year loss of $161.3 million, an improvement from a loss of $167.2 million in 2024.
• Medical Margin: Q4 medical margin was negative $28.7 million, compared to a positive $7.3 million in Q4 2024. Full-year medical margin was $23.5 million, significantly lower than $85.4 million in 2024.

2. Strategic Updates and Business Highlights

• Operational Improvements: Identified $170 million in structural and operational improvements, with 75% expected from contracting and revenue-related actions.
• New Partnership: Announced a partnership expanding into a new Medicare Advantage geography, adding 29,000 members and projected to generate $27 million in revenue for 2026.
• Quality Performance: Achieved 4-star status across 70% of priority Medicare Advantage plans, enhancing value proposition with payers.
• Provider Network: Over half of patients are now served by Tier 1 provider groups, indicating improved clinical integration and accountability.

3. Forward Guidance and Outlook

• 2026 Guidance: Projecting adjusted EBITDA at a midpoint of $10 million, a potential improvement of $170 million from 2025. Expected at-risk membership between 107,000 and 117,000, with total revenue forecasted between $1.5 billion and $1.7 billion.
• Revenue Drivers: Improvement expected from CMS rate increases, contract renegotiations, and ongoing medical cost management initiatives.

4. Bad News, Challenges, or Points of Concern

• Continued Losses: Despite improvements, the company reported significant losses in adjusted EBITDA and medical margin, indicating ongoing financial challenges.
• Operational Execution Risks: The success of the projected improvements is contingent on the timely execution of various operational initiatives, which introduces uncertainty.
• Market Conditions: Competitive pressures and the need for ongoing contract renegotiations may pose risks to achieving the outlined financial targets.

5. Notable Q&A Insights

• Membership Guidance Clarification: The 112,000 at-risk members do not include the additional 29,000 from the new Nebraska agreement, which is a separate addition.
• Glidepath to Risk: The new Nebraska partnership includes a two-year glidepath to full risk, with performance metrics to be met during this period.
• Contract Changes: Improvements in 2026 contracts include better premium rates and adjustments related to Stars performance, indicating a more collaborative approach with payers.

This summary encapsulates the key points from the earnings call, highlighting both the positive strides made by P3 Health Partners and the challenges that remain as they move into 2026.